Retinitis Pigmentosa Clinical Trials

32 recruiting

Retinitis Pigmentosa Trials at a Glance

41 actively recruiting trials for retinitis pigmentosa are listed on ClinicalTrialsFinder across 6 cities in 23 countries. The largest study group is Phase 1 with 13 trials, with the heaviest enrollment activity in Dallas, Portland, and Paris. Lead sponsors running retinitis pigmentosa studies include Columbia University, Frontera Therapeutics, and Kiora Pharmaceuticals, Inc..

Browse retinitis pigmentosa trials by phase

Treatments under study

About Retinitis Pigmentosa Clinical Trials

Looking for clinical trials for Retinitis Pigmentosa? There are currently 32 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Retinitis Pigmentosa trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Retinitis Pigmentosa clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 41 trials

Recruiting
Phase 2

A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa

Retinitis Pigmentosa
Kiora Pharmaceuticals, Inc.36 enrolled5 locationsNCT06628947
Recruiting

Cell Collection to Study Eye Diseases

Retinal DegenerationRetinitis PigmentosaRetinal Disease+1 more
National Eye Institute (NEI)930 enrolled1 locationNCT01432847
Recruiting

Natural History Study of Patients With EYS-Associated RP

Retinitis PigmentosaEye Diseases
Sensor Technology for Deafblind45 enrolled1 locationNCT07228793
Recruiting

Rod and Cone Mediated Function in Retinal Disease

Stargardt's DiseaseRetinal DegenerationRetinitis Pigmentosa
National Eye Institute (NEI)500 enrolled1 locationNCT02617966
Recruiting
Phase 1Phase 2

A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa

Retinitis Pigmentosa
Sumitomo Pharma America, Inc.12 enrolled2 locationsNCT06891885
Recruiting

Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

Retinitis PigmentosaInherited Retinal Degeneration
Jaeb Center for Health Research1,500 enrolled36 locationsNCT05589714
Recruiting
Phase 2

Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)

Retinitis Pigmentosa
jCyte, Inc60 enrolled14 locationsNCT06912633
Recruiting
Early Phase 1

Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients

Retinitis Pigmentosa
Zhongmou Therapeutics12 enrolled1 locationNCT06292650
Recruiting

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

Retinitis PigmentosaStargardt DiseaseStargardt Macular Dystrophy
Ray Therapeutics, Inc.25 enrolled1 locationNCT07502664
Recruiting
Phase 3

A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa

Retinitis Pigmentosa
Janssen Pharmaceutical K.K.4 enrolled1 locationNCT05926583
Recruiting
Phase 2

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

X-Linked Retinitis Pigmentosa (XLRP)
Beacon Therapeutics10 enrolled6 locationsNCT07174726
Recruiting
Phase 1Phase 2

A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)

Retinitis Pigmentosa
Octant, Inc.50 enrolled1 locationNCT07408232
Recruiting
Phase 1Phase 2

BS01 in Patients With Retinitis Pigmentosa

Retinitis Pigmentosa
Bionic Sight LLC20 enrolled1 locationNCT04278131
Recruiting

CNGB1 and Allied Disorders

Retinitis Pigmentosa Associated With CNGB1 Mutations
Columbia University20 enrolled6 locationsNCT04639635
Recruiting
Phase 1Phase 2

A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001

Retinal DegenerationRetinal DiseaseRetinal Dystrophies+2 more
PYC Therapeutics16 enrolled6 locationsNCT06852963
Recruiting
Not Applicable

High Resolution, High-speed Multimodal Ophthalmic Imaging

HypertensionStrokeDiabetes+12 more
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts1,200 enrolled1 locationNCT04129021
Recruiting
Phase 1Phase 2

A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)

Retinitis PigmentosaChoroideremiaNon-Syndromic Rod-Dominant Inherited Retinal Diseases
Kiora Pharmaceuticals, Inc.48 enrolled3 locationsNCT05282953
Recruiting
Phase 1

The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration

Age-Related Macular DegenerationAlcohol Use DisorderRetinitis Pigmentosa+2 more
University of Rochester15 enrolled1 locationNCT06319872
Recruiting
Not Applicable

Pilot Study of AuTNA I

Retinitis Pigmentosa
Eye & ENT Hospital of Fudan University7 enrolled1 locationNCT05853107
Recruiting
Phase 1Phase 2

Promising ROd-cone DYstrophy Gene therapY

Retinitis Pigmentosa
SparingVision33 enrolled6 locationsNCT05748873